Grade 3–4 treatment-related adverse events included anemia (16.6%), leucopenia (100%), thrombocytopenia (33%), febrile neutropenia (grade 3) (50%), CD4 lymphopenia (≥ grade 3) (100%) *. Here, CD4 is linked to anemia.